9592 Background: Five-year survival for stage III and IV ovarian cancer of the epithelial cell origin is less than 30%, despite surgery and chemotherapy, due largely to disease relapse. Tumor-derived heat shock protein (HSP) gp96-peptide complexes can induce tumor-protective T cell immunity in multiple preclinical models. We have initiated the first study of consolidation therapy with autologous gp96 vaccine for stage III/IV ovarian cancer. Methods: All patients have the diagnosis of stage III or IV ovarian cancers. Gp96-peptide complexes are purified from autologous tumors procured at the initial surgery. Patients who have completed standard therapy (Carboplatin/Taxane) and have no evidence of progressive disease are eligible to receive the vaccine. The first 11 patients receive gp96, 25 μg i.d., weekly for 8 weeks. The second group of 11 patients will receive the same dose and schedule of gp96 vaccine, mixed with 100 μg GM-CSF. Patients are followed clinically for toxicity and relapse-free survival, and...